Data as of Nov 26
| +0.1299 / +5.18%|
The 2 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +203.03% increase from the last price of 2.64.
The current consensus among 2 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.